Suppliers / Rivopharm

Rivopharm

Switzerland 167 employees Updated 9 July 2026

Rivopharm is a finished-dose manufacturer based in Switzerland. It appears in 45 regulatory filings across 7 regulators, without an active US DMF or CEP on file. Its filings concentrate with MPA (SE), AIFA (IT) and SWISSMEDIC (CH). Its GMP standing is certified by EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 23 June 2023 as NAI.

0
active US DMFs
0
valid CEPs
4
registered plants 1 with an FDA FEI number
45
filings across 7 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 23 June 2023 NAI US FDA
  • 18 January 2019 VAI US FDA
  • 30 October 2015 VAI US FDA
  • 3 April 2014 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Manno, United Arab Emirates Not on file
MANNO, Switzerland Not on file
Switzerland, Switzerland 3005884589
Manno, Switzerland Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
MPA (SE) 23 None
AIFA (IT) 8 None
SWISSMEDIC (CH) 7 None
BOMRA (BW) 3 None
EDE (AE) 2 None
UZPHARM (UZ) 1 None
EMA None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Rivopharm comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 23 June 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates